Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
Sponsor: Novartis Pharmaceuticals
Summary
CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
4
Start Date
2024-04-16
Completion Date
2039-01-11
Last Updated
2025-10-03
Healthy Volunteers
No
Conditions
Interventions
OTQ923
There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)
Locations (3)
University of Chicago
Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Ctr
New York, New York, United States
St Jude Childrens Research Hospital
Memphis, Tennessee, United States